eDiagnosis(002932.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
eDiagnosis
002932.SZ
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware products.
801.69 B
002932.SZMarket value -Rank by Market Cap -/-

Financial Score

15/06/2026 Update
C
Health Care EquipmentIndustry
Industry Ranking53/66
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-0.23%D
    • Profit Margin-4.96%D
    • Gross Margin50.30%B
  • Growth ScoreE
    • Revenue YoY-25.98%E
    • Net Profit YoY-133.95%E
    • Total Assets YoY-7.39%E
    • Net Assets YoY-5.48%D
  • Cash ScoreC
    • Cash Flow Margin503.18%A
    • OCF YoY-25.98%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreA
    • Gearing Ratio5.78%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    eDiagnosis: The company's stock will be subject to a "Delisting Risk Warning" starting from April 22, 2026, and the stock abbreviation will change from "eDiagnosis" to "*ST Mingde"

    Wallstreetcn·
    SZ
    002932
    +1.29%
    Wallstreetcn·
    SZ
    002932
    +1.29%

    eDiagnosis released its performance for the first three quarters, with a net profit attributable to the parent company of 13.5155 million yuan, a decrease of 83.30%

    Zhitong·
    SZ
    002932
    +1.29%
    Zhitong·
    SZ
    002932
    +1.29%

    eDiagnosis released its performance for the first half of the year, with a net profit attributable to the parent company of 12.4973 million yuan, a year-on-year decrease of 80.82%

    Zhitong·
    SZ
    002932
    +1.29%
    Zhitong·
    SZ
    002932
    +1.29%

    eDiagnosis releases nucleic acid testing solutions for Chikungunya virus and mosquito-borne pathogens

    Zhitong·
    SZ
    002932
    +1.29%
    Zhitong·
    SZ
    002932
    +1.29%

    eDiagnosis launches nucleic acid testing solutions for Chikungunya virus and mosquito-borne pathogens

    Zhitong·
    SZ
    002932
    +1.29%
    Zhitong·
    SZ
    002932
    +1.29%
    © 2026 Longbridge｜Disclaimer